NT-3 Combined with TGF-β Signaling Pathway Enhance the Repair of Spinal Cord Injury by Inhibiting Glial Scar Formation and Promoting Axonal Regeneration
-
Published:2023-06-15
Issue:
Volume:
Page:
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Chen TaibangORCID, He Xiaoqing, Wang Jing, Du Di, Xu Yongqing
Abstract
AbstractThis study investigated the mechanism of neurotrophin-3 (NT-3) in promoting spinal cord injury repair through the transforming growth factor-beta (TGF-β) signaling pathway. A mouse model of spinal cord injury was established. Forty C57BL/6J mice were randomized into model, NT-3, NT-3 + TGF-β1 and NT-3 + LY364947 groups. The Basso–Beattie–Bresnahan (BBB) scores of the NT-3 and NT-3 + LY364947 groups were significantly higher than the model group. The BBB score of the NT-3 + TGF-β1 group was significantly lower than NT-3 group. Hematoxylin-eosin staining and transmission electron microscopy showed reduction in myelin sheath injury, more myelinated nerve fibers in the middle section of the catheter, and relatively higher density and more neatly arranged regenerated axons in the NT-3 and NT-3 + LY364947 groups compared with the model and NT-3 + TGF-β1 groups. Immunofluorescence, TUNEL and Western blot analysis showed that compared with model group, the NEUN expression increased, and the apoptosis and Col IV, LN, CSPG, tenascin-C, Sema 3 A, EphB2 and Smad2/3 protein expression decreased significantly in the NT-3 and NT-3 + LY364947 groups; the condition was reversed in the NT-3 + TGF-β1 group compared with the NT-3 group. NT-3 combined with TGF-β signaling pathway promotes astrocyte differentiation, reduces axon regeneration inhibitory molecules, apoptosis and glial scar formation, promotes axon regeneration, and improves spinal cord injury.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology
Reference42 articles.
1. Hu, X. C., Lu, Y. B., Yang, Y. N., Kang, X. W., Wang, Y. G., Ma, B., & Xing, S. (2021). Progress in clinical trials of cell transplantation for the treatment of spinal cord injury: How many questions remain unanswered? Neural Regen Res, 16(3), 405–413. 2. Johnson, L. D. V., Pickard, M. R., & Johnson, W. E. B. (2021). The comparative effects of mesenchymal stem cell transplantation therapy for spinal cord injury in humans and animal models: A systematic review and meta-analysis. Biology (Basel), 10(3), 230. 3. Ruzicka, J., Machova-Urdzikova, L., Gillick, J., Amemori, T., Romanyuk, N., Karova, K., Zaviskova, K., Dubisova, J., Kubinova, S., Murali, R., Sykova, E., Jhanwar-Uniyal, M., & Jendelova, P. (2017). A comparative study of three different types of stem cells for treatment of rat spinal cord injury. Cell Transplantation, 26(4), 585–603. 4. Jin, M. C., Medress, Z. A., Azad, T. D., Doulames, V. M., & Veeravagu, A. (2019). Stem cell therapies for acute spinal cord injury in humans: A review. Neurosurg Focus, 46(3), E10. 5. Mohamadi, Y., Noori Moghahi, S. M. H., Mousavi, M., Borhani-Haghighi, M., Abolhassani, F., Kashani, I. R., & Hassanzadeh, G. (2019). Intrathecal transplantation of Wharton’s jelly mesenchymal stem cells suppresses the NLRP1 inflammasome in the rat model of spinal cord injury. Journal Of Chemical Neuroanatomy, 97, 1–8.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|